We have created an infographic exploring some of the key facts about Non-Hodgkin lymphoma, including its current treatment options and emerging therapies.
Browsing: emerging therapies
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
The Phase III TAILORx clinical trial results indicate that most women with a specific early-stage breast cancer and midrange score on a gene expression assay do not need chemotherapy after surgery.
Results from a Phase lll clinical trial demonstrate the success of a new targeted medicine, taselisib, in treating advanced breast cancer.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
A novel three-dimensional high-throughput screening approach allows researchers to identify inducers of a mutant KRAS selective lethal phenotype.
This world-first-treatment could potentially offer hope to lung cancer patients with previously untreatable lung tumors.
Advanced triple-negative breast cancer patients who have inherited a BRCA mutation are twice as likely to benefit from carboplatin as docetaxel, a novel study suggests.
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).
Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).